Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperReviewResearchpeer-review

  • Mona Sadat Mirtaleb, Department of Energy and Environmental Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran, Iran, Islamic Republic of
  • Amir Hossein Mirtaleb, Tarbiat Modares Univ, Tarbiat Modares University, Dept Mat Engn, Iran, Islamic Republic of
  • Hassan Nosrati
  • ,
  • Jalal Heshmatnia, Shahid Beheshti University of Medical Sciences, Iran, Islamic Republic of
  • Reza Falak, Iran University of Medical Sciences
  • ,
  • Reza Zolfaghari Emameh, National Institute of Genetic Engineering and Biotechnology, Iran, Islamic Republic of
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2020 and coronavirus disease 19 (COVID-19) was later announced as pandemic by the World Health Organization (WHO). Since then, several studies have been conducted on the prevention and treatment of COVID-19 by potential vaccines and drugs. Although, the governments and global population have been attracted by some vaccine production projects, the presence of SARS-CoV-2-specific antiviral drugs would be an urge necessity in parallel with the efficient preventive vaccines. Various nonspecific drugs produced previously against other bacterial, viral, and parasite infections were recently evaluated for treating patients with COVID-19. In addition to therapeutic properties of these anti-COVID-19 compounds, some adverse effects were observed in different human organs as well. Not only several attentions were paid to antiviral therapy and treatment of COVID-19, but also nanomedicine, immunotherapy, and cell therapy were conducted against this viral infection. In this review study, we planned to introduce the present and potential future treatment strategies against COVID-19 and define the advantages and disadvantages of each treatment strategy.
Original languageEnglish
Article number111518
JournalBiomedicine and Pharmacotherapy
Volume138
ISSN0753-3322
DOIs
Publication statusPublished - Jun 2021

See relations at Aarhus University Citationformats

ID: 213170585